Country: Canada
Language: English
Source: Health Canada
DEFERASIROX
TARO PHARMACEUTICALS INC
V03AC03
DEFERASIROX
360MG
TABLET
DEFERASIROX 360MG
ORAL
15G/50G
Prescription
HEAVY METAL ANTAGONISTS
Active ingredient group (AIG) number: 0151733006; AHFS:
APPROVED
2020-11-05
_Taro-Deferasirox (Type J) Page 1 of 54 _ _ _ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TARO-DEFERASIROX (TYPE J) deferasirox Tablets, 90 mg, 180 mg, 360 mg; oral Iron chelating agent Taro Pharmaceuticals Inc. 130 East Drive, Brampton Ontario L6T 1C1 Date of Initial Authorization: November 05, 2020 Date of Revision: June 16, 2023 Submission Control No: 268760 _Taro-Deferasirox (Type J) Page 2 of 54 _ _ _ _ _ RECENT MAJOR LABEL CHANGES 3 Serious Warnings and Precautions Box 06/2023 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations; 4.2 Recommended Dose and Dosage Adjustment 06/2023 7 WARNINGS AND PRECAUTIONS; Ear/Nose/Throat; Hepatic/Biliary/Pancreatic; Monitoring and Laboratory Tests; Renal 06/2023 7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations, 7.1.3 Pediatrics (2 to 16 years of age) 06/2023 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ..................................................................................................... 2 TABLE OF CONTENTS ..................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION.................................................................................. 4 1 INDICATIONS ......................................................................................................................... 4 1.1 Pediatrics ............................................................................................................................ 4 1.2 Geriatrics ............................................................................................................................ 4 2 CONTRAINDICATIONS ............................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................................ 5 Serious Warnings and Precautions .............................................................................................. Read the complete document